Baird to Exact Sciences investors: ‘Respect the range’

Exact Sciences Corp. shares took a sharp hit earlier this week when its preliminary fourth-quarter results announcement showed test volumes for its trademarked Cologuard stool DNA-based colorectal cancer tests were within the company's guidance.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news